Drug-drug interactions in inpatient and outpatient settings in Iran: a systematic review of the literature by Ehsan Nabovati et al.
Nabovati et al. DARU Journal of Pharmaceutical Sciences 2014, 22:52
http://www.darujps.com/content/22/1/52REVIEW ARTICLE Open AccessDrug-drug interactions in inpatient and
outpatient settings in Iran: a systematic review
of the literature
Ehsan Nabovati1,2, Hasan Vakili-Arki1, Zhila Taherzadeh3,4, Mohammad Reza Hasibian6, Ameen Abu-Hanna7
and Saeid Eslami5,6,7*Abstract
Drug-drug interactions (DDIs) are an important type of adverse drug events. Yet overall incidence and pattern of
DDIs in Iran has not been well documented and little information is available about the strategies that have been
used for their prevention. The purpose of this study was to systematically review the literature on the incidence
and pattern of DDIs in Iran as well as the used strategies for their prevention. PubMed, Scopus, electronic Persian
databases, and Google Scholar were searched to identify published studies on DDIs in Iran. Additionally, the
reference lists of all retrieved articles were reviewed to identify additional relevant articles. Eligible studies were
those that analyzed original data on the incidence of DDIs in inpatient or outpatient settings in Iran. Articles about
one specific DDI and drug interactions with herbs, diseases, and nutrients were excluded. The quality of included
studies was assessed using quality assessment criteria. Database searches yielded 1053 potentially eligible citations.
After removing duplicates, screening titles and abstracts, and reading full texts, 34 articles were found to be relevant.
The quality assessment of the included studies showed a relatively poor quality. In terms of study setting, 18 and 16
studies have been conducted in inpatient and outpatient settings, respectively. All studies focused on potential DDIs
while no study assessed actual DDIs. The median incidence of potential DDIs in outpatient settings was 8.5% per
prescription while it was 19.2% in inpatient settings. The most indicated factor influencing DDIs incidence was patient
age. The most involved drug classes in DDIs were beta blockers, angiotensin-converting-enzyme inhibitors (ACEIs),
diuretic agents, and non-steroidal anti-inflammatory drugs (NSAIDs). Thirty-one studies were observational and three
were experimental in which the strategies to reduce DDIs were applied. Although almost all studies concluded that
the incidence of potential DDIs in Iran in both inpatient and outpatient settings was relatively high, there is still no
evidence of the incidence of actual DDIs. More extensive research is needed to identify and minimize factors
associated with incidence of DDIs, and to evaluate the effects of preventive interventions especially those that utilize
information technology.
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Adverse drug events (ADE) are the most common compli-
cations related to medication therapy among patients [1-3].
ADEs are common, costly, and may have life-threatening
consequences [4-6]. The high incidence of medication use
in medical therapy and possibility of human errors increase
the incidence risk of these adverse events.
Drug-drug interactions (DDIs) are an important sub-
group of ADEs [7] which are highly prevalent in patients
receiving multiple-drug treatment [8]. DDIs may lead
to severe adverse events which can result in patient
hospitalization. Some studies have estimated that up to
3% of hospital admissions are caused by DDIs [9-11].
Although it is widely recognized that DDIs may harm
patients, their incidence is still high [12]. The majority
of these interactions occurred because either prescribers
do not consider them relevant [13] or prescribers’ know-
ledge of DDIs is generally poor [14]. Hence, they could
be prevented through applying proper interventions. This
can improve the quality of drug therapy and increase pa-
tient safety. Interventions aimed at reducing DDIs are
likely to be more effective, if before their development, the
incidence and pattern of DDIs are determined accurately.
Estimates about the incidence of DDIs in different coun-
tries vary from 6% to 70% due to variability in methodolo-
gies and settings [12,15-18]. Because of this variation, it is
important that the related evidence is aggregated and
summarized in each country, separately. To our know-
ledge, three systematic reviews in the literature reviewed
DDIs studies. Espinosa-Bosch et al. conducted a review on
English and Spanish studies which had reported incidence
of DDIs in hospital care [19]. They showed that around
20% of hospitalized patients were susceptible to DDIs and
incidence was higher in patients with heart disease and
the elderly. Another review has summarized and described
findings from studies that assessed harmful DDIs in eld-
erly patients [20]. It has been conclusively shown that sig-
nificant harm is associated with DDIs in elderly patients.
Also, Riechelmann and Giglio systematically reviewed the
studies, published in English, Portuguese, and Spanish, on
the frequency of DDIs in cancer patients [21]. They esti-
mated that about one-third of cancer patients are at the
risk of DDIs.
None of the DDIs systematic reviews were conducted
in a developing country. In Iran, several DDIs studies
have been conducted, but there is uncertainty about
their overall incidence, pattern of the most involved
medication classes, and the possible interventions and
their effectiveness.
The objective of this systematic review is to identify
and summarize all evidence concerning DDIs in Iran as
an example of a developing country. In this study we ad-
dress four questions: (1) what is the incidence and pattern
of DDIs?; (2) which factors are associated to incidence ofDDIs?; (3) what interventions have been used to prevent
this type of medication errors?; (4) which interventions
have been effective in reducing DDIs?
Methods
Search strategy and data sources
A comprehensive search strategy for original articles was
developed using terms related to drug interaction (drug
interaction, adverse drug event, adverse drug reaction,
medication error, prescription error) combined with terms
related to Iran (Iran, Iranian).
The following electronic databases were searched for
English articles using customized search strategies: MED-
LINE/PubMed and Scopus. Persian Electronic databases in-
cluding Scientific Information Database (SID), IranMedex,
IranDoc, and MagIran were searched using Persian terms
equivalent to the English terms mentioned above. The
electronic databases were last searched on March 2013. To
ensure that no article is missed, we also searched Google
Scholar using both Persian and English search terms.
In a final search, the reference lists of all identified
articles were also reviewed to identify additional relevant
articles (snowball method).
Inclusion and exclusion criteria
All published studies on children, adults, and elderly pa-
tients that were conducted in either an outpatient or in-
patient setting in Iran and published either in English or
Persian were included. Various types of research designs
including observational studies that reported the inci-
dence of DDIs and interventional studies that evaluated
an intervention on reduction of DDIs were included.
Articles about one specific DDI and drug interactions
with herbs, diseases, and nutrients were excluded. More-
over, we excluded letters, opinions, conference papers,
and dissertations.
Review procedure and data extraction
A reviewer conducted the search for the articles. Two
reviewers (including the one conducting the literature
search) considered the inclusion and exclusion criteria
independently and screened the title and abstract of all
potential relevant articles. Any discrepancies on the eli-
gibility of the articles were resolved by discussion among
the reviewers. After the inclusion process, the full text of
eligible articles for the purposes of this review was re-
trieved. In the case of inaccessibility, the full text was re-
quested from the authors by email. The full text of each
eligible article was reviewed and abstracted into a pre-
specified form.
The data abstraction form was used to collect infor-
mation on the following characteristics: objectives, set-
ting, study period, type of study, sampling, data source,
DDIs reference, main findings, details of reported DDIs,
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of DDIs, interventions and their outcomes, and other
relevant information.
Quality assessment of the included studies
There is no tool that assesses the quality of DDIs studies.
A twelve-item quality assessment tool (Table 1) was devel-
oped based on the criteria taken from the tools for asses-
sing the quality of medication error studies [22,23]. Overall
quality scores ranged from 0 to 12 (0 to 6 points = poor, 7
to 9 points = moderate, 10 to 12 points = high). Two re-
viewers independently scored the quality criteria for
each included study and a third reviewer resolved any
discrepancies.
Due to variations in the methods used to report on




The flow diagram of literature search is shown in Figure 1.
Electronic literature search on MEDLINE/PubMed, Sco-
pus and Persian databases identified a total of 1053
records. 861 unique records remained after excluding du-
plicates. After reviewing titles and abstracts and applying
inclusion and exclusion criteria, 54 articles were chosen
for full text review. By hand-searching the references list,
two additional relevant articles were also identified. Subse-
quently, the full texts of these potentially relevant articles
were obtained except one [24] (even after contacting its
authors by email). After detailed full text review of 55
articles, a further 21 articles were excluded, because they
only assessed pattern of drug prescribing, only evaluatedTable 1 The tool used to rate the quality of the included
studies
Quality assessment criteria Score
1) Aims/objectives of the study clearly stated 1
2) Definition of what constitutes a DDI 1
3) DDI categories specified 1
4) DDI categories defined 1
5) Mention of DDI reference 1
6) Data collection method described clearly 1
7) Setting in which study was conducted described 1
8) Study subjects described 1
9) Sampling and calculation of sample size described
(unit of measurement)
1
10) Potential or actual DDIs assessed 1
11) Measures in place to ensure that results are valid 1
12) Limitations of study listed 1
Maximum score 12 points
Each item is related to a quality assessment criterion with score 0 or 1.quality of drug prescribing, or only estimated prescription
errors without referring to DDIs. Finally, 34 relevant
articles that met our specified criteria were included in
this review.
General characteristics of the included studies
The oldest study was published in 1997 and the most re-
cent one in 2013. Twenty-one studies (62%) had been writ-
ten in Persian and 13 (38%) were in English. In terms of
study setting, 15 (44%) and 19 (56%) studies have been con-
ducted in inpatient and outpatient settings, respectively. In
terms of study design, 31 studies (91%) were observational
and three (9%) were experimental. The majority of studies,
20 out of 34, had used Drug Interaction Facts as their DDI
compendia. Table 2 shows the general characteristics of the
included studies.
Quality of the included studies
After the quality assessment of individual studies, none of
them fulfilled all the quality criteria. Three studies (9%)
were of higher quality (10 points), 16 studies (47%) were
of moderate quality (7 to 9 points), and 15 studies (44%)
were of poor quality (0 to 6 points). In terms of the quality
assessment criteria, no study assessed actual DDIs, only
four studies (12%) listed their limitations, and 15 studies
(44%) defined DDIs categories.
Findings of the included studies
Twenty-five (73.5%) studies reported the overall incidence
of potential DDIs in the study population (prescription or
patient). Nine studies (26.5%) have not reported the over-
all incidence of DDIs. Among the studies performed in
outpatient settings, nine studies assessed the overall inci-
dence of potential DDIs in prescriptions in the population
for all types of drugs. The median incidence of potential
DDIs in prescriptions of these studies was 8.5% (Inter-
quartile Range (IQR): 8.4-10.1). The other outpatient
studies focused on the incidence of potential DDIs
in cardiovascular drugs (DDIs percentage = 50%) [26],
non-steroidal anti-inflammatory drugs (NSAIDs) (DDIs
percentage = 49%) [30], antidepressant drugs (DDIs per-
centage =22%) [29], dental drugs (DDIs percentage =27%)
[39], and elderly people (DDIs percentage =10% and
14%) [47,51].
Among the studies performed on inpatient prescrip-
tions, four assessed the overall incidence of potential DDIs
in prescriptions for all groups of patients in all depart-
ments and for all drug classes [24,25,52,53]. The median
incidence of potential DDIs in these studies was 19.2%
(IQR: 15.5-22). The focus of one study in inpatient setting
was on pediatric patients (DDIs percentage = 21%) [37].
The two studies that focused on potential DDIs in hospi-
talized patients in the hematology and oncology depart-
ments reported the incidence of 38% and 63% [55,57].
Records identified for 
articles in Persian: 143
SID: 30 IranDoc: 46
IranMedex:46    MagIran: 21
Records identified for 
articles in English: 910
PubMed: 633
Scopus: 277
Records after removal of 
duplicates: 861
Records screened by title 
and abstract: 861
Full-text articles assessed 
for eligibility: 55
Studies included in 
quantitative synthesis: 34
Records excluded: 806
Full-text articles excluded: 21
• Studies only assessed pattern of 
drug prescribing
• Studies only evaluated quality of 
drug prescribing
• Studies only estimated prescribing 
errors without referring to DDIs
Figure 1 Flow diagram of the literature search and study selection. The search strategy focused on studies that analyzed original data on
the incidence of DDIs in inpatient or outpatient settings in Iran.
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to 62%) have grouped the identified DDIs in terms of se-
verity and reported the percentage of major, moderate,
and minor DDIs separately. The median percentage of
major, moderate, and minor DDIs in these studies were
7.7% (IQR: 4.4-11.6), 67.4% (IQR: 51.3-75.3), and 24.2%
(IQR: 16.4-41.9), respectively. Six additional studies (17.5%)
have calculated the percentage of prescriptions with at least
one DDI grouped by severity. The median percentage of
prescriptions with major, moderate, and minor DDIs were
0.8% (IQR: 0.7-1.3), 10.2% (IQR: 5.6-11.2), and 9.6% (IQR:
3.6-22.8), respectively.
Fifteen studies (44%) have confirmed the association
between the number of medications and the incidence
of DDIs. The influence of other factors on incidence of
DDIs was mentioned in 11 studies (32%). These factors
are listed in Table 3.
Twenty three studies (67.6%) have determined the most
frequent DDIs. Among them, eight studies have also clas-
sified the most frequent DDIs by severity. The most fre-
quent major DDIs in the studies, which ranked in the first
10 identified DDIs, are listed in Table 4. As this table
shows, five studies have ranked the major interaction be-
tween digoxin and furosemide among the most frequent
interactions.
Names and classes of drugs which mostly contributed
to DDIs have been reported by 14 studies (Table 5).Beta blockers, angiotensin-converting-enzyme inhibi-
tors (ACEIs), diuretic agents, and NSAIDs have been
mentioned most often as drug classes. Digoxin contrib-
uted the most to major DDIs.Interventional studies
Among the included studies, only three were interven-
tional. All three were quasi experimental and have been
conducted in outpatient settings. In the first study
[34], the effects of face to face education, information
feedback, and pamphlets designation were evaluat-
ed. The study shown that potential DDIs in general
practitioners and specialists’ prescriptions decreased
(severe: 1.6% before vs. 0.24% after, moderate: 10.6%
before vs. 2% after, minor: 5.1% before vs. 2.1% after,
p-value < 0.001). In the second study [35], individual-
ized feedback and workshop training programs were
used. The study mentioned that potential DDIs with first
significance degree (based on Drug Interactions Facts™) in
general practitioners’ prescriptions reduced significantly
(0.4% before vs. 0.05% after interventions, p-value < 0.001).
The third study [46] evaluated the effect of face-to-face
training, audit feedback, and educational notes on the
major DDIs in general practitioners and specialists’ pre-
scriptions. It demonstrated that severe DDIs diminished
significantly (1.5% before vs. 0.4% after, p-value < 0.05).
Table 2 General characteristics of the included studies




Design Duration Sample Size/Unit
of Analysis
Drug interaction database
[24] 1997 Persian All Outpatient All Observational
(Retrospective)
2 months 3117 Prescriptions -




3 months 1000 Prescriptions -




6 months 1038 Prescriptions Drug Interaction Facts
[27] 2000 Persian All Outpatient All Observational
(Retrospective)
12 Months 4750 Prescriptions Drug Interaction Facts
[28] 2001 Persian All Outpatient All Observational
(Retrospective)
3 months 1100 Prescriptions Drug Interaction Facts




6 months 3000 Prescriptions Drug Interaction Facts
[30] 1999-2001 Persian All Outpatient NSAID Observational
(Retrospective)
36 months 1927 Prescriptions Hansten Drug Interactions
[31] 2000 Persian All Outpatient All Observational
(Retrospective)
6 months 3000 Prescriptions Drug Interaction Facts
[32] 2000 Persian All Outpatient All Observational
(Retrospective)
12 months 1800 Prescriptions Drug Interaction Facts
[33] 2001 Persian All Outpatient All Observational
(Retrospective)
6 months 5300 Prescriptions Drug Interaction Facts
[34] 2005-2006 Persian All Outpatient All Interventional
(Quasi Experimental)
6 months 5300 Prescriptions –
43 Prescribers
Drug Interaction Facts
[35] 2002-2003 Persian All Outpatient All Interventional
(Quasi Experimental)
12 months 6704 Prescriptions –
119 Prescribers
Drug Interaction Facts
[36] 2006 Persian All Inpatient All Observational
(Retrospective)
1 month 6969 Prescriptions -
[37] 2004 Persian Pediatrics Inpatient All Observational
(Retrospective)
6 months 898 Medical Records Drug Interaction Facts
[38] 2008 Persian All Outpatient All Observational
(Retrospective)
6 months 167305 Prescriptions -
[39] 2005 – 2006 Persian All Outpatient Dental Observational
(Retrospective)
6 months 666 Prescriptions -






3 months 150 Patients Food and Drug
Administration Package
[41] 2006 – 2007 Persian All Inpatient All Observational
(Retrospective)



















Table 2 General characteristics of the included studies (Continued)
[42] 2009 – 2010 Persian All Inpatient (ICU) All Observational
(Retrospective)
12 months 371 Medical Records Drug Interaction Facts






4 months 1435 Patients Food and Drug Administration
Package
[44] 2009 Persian Elderly Inpatient (ICU) All Observational
(Retrospective)
12 months 70 Patients Drug Interaction Facts





6 months 3130 Prescriptions Drug Interaction Facts
[46] 2002 English All Outpatient All Interventional
(Quasi Experimental)
6 months 5600 Prescriptions Drug Interaction Facts
[47] 2000 English Elderly Outpatient All Observational
(Retrospective)
2 months 3000 Prescriptions Drug-Reax (Micromedex)
[48] 2005 English All Inpatient (ICU) All Observational
(Retrospective)
6 months 567 prescriptions Drug Interaction Facts
[49] 2006 – 2008 English All Outpatient All Observational
(Retrospective)
24 months 11,562,808 prescriptions Drug Interaction Facts
[50] 2007 – 2009 English All Outpatient All Observational
(Retrospective)
30 months 44,567,750 Prescriptions Drug Interaction Facts
[51] 2005 – 2006 English Elderly Outpatient All Observational
(Retrospective)
12 months 2041 Patients Swedish Classification System
[52] 2001 English All Inpatient All Observational
(Prospective)
3 months 519 Prescriptions Drug Interaction Facts
[53] 2010 English Adults Inpatient All Observational
(Retrospective)
12 months 1000 Prescriptions A computerized DDI database
system (Prescription Analyzer
2000, Sara Rayane Co., Iran)
[54] 2012 English All Inpatient (ICU) All Observational
(Prospective)
20 days 101 patients Drug Interaction Facts








6 months 83 patients On-Desktop Lexi-Interact
[56] 2011 English All Inpatient (Post-ICU) All Observational
(Prospective)
6 months 203 patients Online Lexi-Interact








































Elderly: 3 Inpatient: 15 Interventional: 3 Maximum:
36 months
Patient: 11 Patients: Others: 9
War-injured: 2 Minimum: 70
ICU: 6 Maximum:
2041























Table 3 Factors associated with incidence of DDIs
Factors Description
Physician Gender The DDI incidence was significantly higher among male doctors [33,46].
Age Older physicians prescribed medications with more major DDIs than younger physicians (Not statistically
significant) [46].
Specialty Major DDIs were higher in the prescriptions of specialist practitioners in comparison to general practitioners
(cardiologists and internists ranked top on the list, while dermatologists ranked the lowest) [50].
General practitioners had more prescriptions with major DDIs than specialists (statistically significant) [33].
Significant level 1 DDIs1 were higher in prescriptions of internal specialists and cardiologists than other
practitioners [31].
Significant level 2 DDIs1 were higher in prescriptions of obstetrician and gynecologist than other
practitioners [31].
Significant level 3 DDIs1 were higher in prescriptions of general physicians than specialists [31].
General physicians prescribed more medications with major DDIs than specialists (Not statistically
significant) [46].
Number of Prescriptions Physicians with 150 or more prescriptions in one month had more DDIs than the others (statistically
significant) [33].
Patient Gender DDIs were significantly higher in female patients [53].
DDIs were significantly higher in male patients [42].
Age Clinically relevant DDIs were more common for patients 75 years or above than other patients [51].
DDIs were significantly higher in patients aged over 60 years than other patients [42,53,57].
Disease DDIs were significantly higher in cardiology patients than other patients [53].
DDIs were higher in Hematologic cancer patients than patients suffer from other diseases [57].
DDIs were higher in patients whose source of cancer was in different specific organs than other
cancer patients [57].
Length of Hospital Stay DDIs were higher in patients with longer hospital stay than other patients [42,57].
Department DDIs occurred in surgery department more than the other departments [36].
Drug DDIs was significantly higher in patients who have been prescribed digoxin than other patients [53].
1Significance rating is based on Drug Interactions Facts™. The factors are related to physicians and patients’ characteristics.
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This study aimed to provide an overview of the incidence
and pattern of DDIs and associated factors in Iran, as an
example of a developing country. This is the first review
study that summarizes the available evidence of DDIs in
Iran.
We identified and described the results of 34 relevant
studies addressing the key questions of this review. The
overall quality of DDIs studies in Iran was relatively poor,
perhaps due to lack of a standard guideline for designing
methodology and reporting results of medication error
studies. The median incidence of potential DDIs in pre-
scriptions in outpatient settings was 8.5%, while it was
19.2% in inpatient settings. Patient age was the most re-
ported factor influencing the incidence of DDIs. Only
three studies were interventional, and all showed signifi-
cant reduction in potential DDIs.
Our results show that all DDIs studies in Iran assessed
potential DDIs, while no study was performed on actual
DDIs. Actual DDIs are interactions that actually lead to
adverse clinical events in patients. Espinosa-Bosch et al.
found a larger number of studies on potential DDIs thanon actual DDIs in developed countries (42 vs. 5 studies)
[19]. From eight studies included in the review of DDIs
in oncology, six assessed potential DDIs while two reported
actual DDIs [21]. Our findings in accordance with those
from studies in developed countries confirm that there is
little evidence of the incidence of actual DDIs in compari-
son to potential DDIs in the literature. The reason for this
may be that identifying actual DDIs is much more compli-
cated than potential DDIs. The majority of the included
studies were retrospective which had used computerized
programs to review physicians’ orders and prescriptions
and to identify potential DDIs. However, to identify actual
DDIs, it is required to find the adverse events and confirm
that they are a result of simultaneously administering two
drugs in the patient regarding his/her condition. The ad-
verse events from DDIs are either not identified or not
documented accurately. It should be noted that due to in-
herent and recall biases and also ethical considerations, the
conduction of study designs for assessing actual DDIs may
be challenging.
We showed the overall incidence of DDIs in prescrip-
tions in inpatient and outpatient settings reported by
Table 4 The most frequent major DDIs
The most frequent major DDIs References
Digoxin + Furosemide [25-27,50,53]
Captopril + Triamterene-H [38,50]
Carvedilol + Salbutamol(Albuterol) [56,57]
Aspirin + Clopidogrel [56]
Clopidogrel + Omeprazole [56]
Pantoprazole + Clopidogrel [56]
Aspirin +Warfarin [56]
Haloperidol + Propranolol [50]
Amitriptyline + Clonidine [50]
Chlorpromazine + Propranolol [50]
Propranolol + Verapamil [50]
Amiodaron + Digoxin [50]
Gemfibrozil + Atorvastatin [50]
Cyclosporine + Fluconazole [55]
Cyclosporine + Phenytoin [55]
Atorvastatin + Fluconazole [55]
Lovastatin + Gemfibrozil [55]
Arsenic Trioxide + Fluconazole [55]
Aspirin + Ibuprofen [32]
Theophylline + Propranolol [32]
Pseudoephedrine + Furazolidone [32]
Dextromethorphan + Furazolidone [32]
Tranylcypromine + Levodopa [29]
Clomipramine + Furazolidone [29]
Clonazepam + Olanzapine [43]
Digoxin + Verapamil [46]
Rifampin + Isoniazid [48]
Verapamil + Erythromycin [53]
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outpatient: median = 19.2%, IQR: 15.5-22). The high in-
cidence of DDIs may be associated with high number of
drugs per prescription. The mean number of drugs per
prescription in Iran is relatively high [58]. This mean
number for the outpatient setting was 3.16 and 3.05 in
2010 and 2011, respectively, and 17% and 15% of these
prescriptions involved more than four drugs in those
years. No similar review aggregated the reported inci-
dence of DDIs in the general population. The other re-
view studies on DDIs have been conducted on either a
specific group of patients, e.g. elderly, hospitalized pa-
tients, or specific types of drugs e.g. cardiovascular.
The aggregation and comparison of the results of the
included studies showed a wide variability of DDIs inci-
dence estimates in the Iranian healthcare community.
Relatively few studies which were performed in the gen-
eral population in developed countries also showed awide variability of estimates on incidence of DDIs (i.e.
9.8% in Finland [59], 18.5% in Greece [17]). Moreover, a
systematic review on incidence of medication errors in
Iran showed a wide variability of estimates [60]. Different
study methods, various drug interaction databases, diverse
study populations, different sample sizes, and some other
factors have caused this considerable variability; therefore,
direct comparison between the studies is impossible. Max-
imum incidence of potential DDIs in prescriptions (50%)
was reported in a study which assessed DDIs of cardiovas-
cular drugs in outpatient prescriptions [26]. Similarly, the
findings obtained in a study from a developed country
showed that 80% of elderly hospitalized patients with heart
diseases were susceptible to DDIs [61]. The high number
of prescribed drugs and also frequent prescribing of some
drugs with many possible DDIs may cause the high inci-
dence of DDIs in this group of patients. One included
study in our review reported the incidence of potential
DDIs among cancer patients as 37.5% [57]. A study con-
ducted in a developed country has shown that 27% of can-
cer patients were subject to DDIs [62]. Supporting the
results of these studies, a review on DDIs among cancer
patients reported that approximately one-third of cancer
patients are susceptible to DDIs [21]. High growth in the
number of new anti-cancer drugs may be one of the main
reasons for this.
Incidence of DDIs may be associated with characteristics
of patients, prescribers and pharmacists, or some barriers
such as insufficient communication between these groups.
Good communication between prescribers and pharma-
cists is crucial to reduce the risks of DDIs [63]. Among
studies conducted in Iran, no study has assessed pharma-
cists’ factors and communication between participants as
determinants of DDIs. One review paper specified poten-
tial determinants of DDIs associated with pharmacists’
characteristics [64]. In that review, the relationship be-
tween pharmacists and prescribers, quality of signals from
surveillance programs, pharmacists’ workload, and also
availability, quality, and sensitivity of DDIs softwares have
been mentioned as the main potential factors that contrib-
ute to the occurrence of DDIs. The Iranian studies showed
that having heart disease, being old, and receiving digoxin
were the main patient factors associated with high
incidence of DDIs. Similarly, the findings from another re-
view on the incidence of DDIs in a developed country
highlighted these risk factors [19]. Many studies have em-
phasized that the high incidence of DDIs in the elderly is
due to physiological changes related to age, suffering from
multiple diseases, and a high rate of medication use. The
results reported by Juurlink et al. [7], which show that di-
goxin toxicity due to DDIs leads to elderly hospitalization,
is in line with the results of the Iranian studies. Concern-
ing prescribers’ factors, DDIs were higher in the prescrip-
tions of male prescribers and physicians with greater
Table 5 The most common drugs contributing to DDIs
Names and classes of drugs Percentage of
identified DDIs
Reference
Beta Blockers 35.21% [26]
Inotropic Drugs e.g. Digoxin 15.94%
ACEIs1 e.g. Captopril 15.35%
Diuretics e.g. Furosemide 14.66%
Calcium Channel Blockers e.g.
Diltiazem
7.33%







Digoxin 50% of severe DDIs [27]
Gentamicin 26.5% of moderate
DDIs




Tricyclic Antidepressant 72.7% [29]
MAOIs4 25.2%
SRIs3 2.1%
Antibiotics Not specified [24]
Central Nervous System Drugs Not specified
NSAIDs2 Not specified
Antidepressant 52% [40]




















Table 5 The most common drugs contributing to DDIs
(Continued)
Contraceptive LD 2.7%
Digoxin Not specified [50]
Diuretics Not specified








Cardiovascular Drugs Not specified [52]
Digoxin Most common in
severe DDIs
[53]
ACEIs Most common in
severe and moderate
DDIs
Beta Blockers Most common in
moderate DDIs
Fluoroquinolones Most common in
moderate DDIs
Antacids Most common in
moderate DDIs
Phenytoin Not specified [54]
Antimycotics for systemic use5 31.35% [55]
Immunosuppressants 13.51%
Sulfonamides and Trimethoprim 9.73%
Antiepileptics 8.11%
Antiemetics and Antinauseants 7.02%
Antigout Preparations 4.05%
Corticosteroids for Systemic Use,
Plain
3.78%
Other Antineoplastic Agents 2.43%
Direct Acting Antivirals 2.43%
Other Beta-lactam Antibacterials 2.16%
Names and classes of drugs which mostly contributed to DDIs and percentage
of identified DDIs by the relevant studies are shown.
1ACEIs: Angiotensin-Converting-Enzyme inhibitors.
2NSAIDs: Non-Steroidal Anti-Inflammatory Drugs.
3SSRIs: Selective Serotonin Reuptake Inhibitors.
4MAOIs: Monoamine Oxidase Inhibitors.
5Medication classes categorized by the Anatomical Therapeutic Chemical (ATC)
classification system of the World Health Organization.
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to the fact that male and busy physicians may less consider
the possibility of DDIs during the prescription phase. So
far, no study has assessed pharmacological knowledge of
prescribers specifically about DDIs.
Drugs most contributing to major DDIs were digoxin,
followed by beta blockers, ACEIs, diuretic agents, and
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quently prescribed to patients with heart diseases; there-
fore, this may be one of the reasons why DDIs are
highly prevalent in these patients. These results are in
the same line as two other reviews which mainly in-
cluded studies from developed countries [19,20].
The included studies in this review have used various
DDIs compendia, mostly (59%) Drug Interaction Facts.
Studies have shown that there are discrepancies between
DDI compendia [65,66]. In addition, other studies showed
that the various performance measures used (such as ac-
curacy, sensitivity, and specificity) of multiple DDI identify-
ing software vary [67-69]. Therefore, one should consider
these discrepancies in the resources when comparing the
result of the DDI related studies. Clinical relevancy of
DDIs is another important issue that should be consid-
ered when interpreting DDI related study results, as
well as in practice.
Despite the high incidence of DDIs in Iran, only three
studies implemented interventions to reduce them
[34,35,46]. Two studies evaluated the effects of educa-
tional interventions on reduction of DDIs [34,46] and
one study evaluated the effect of audit feedback on the
quality of prescriptions [35]. The studies showed signifi-
cant reduction of DDIs after the interventions. In recent
years, computerized systems have been involved in medi-
cation error reduction strategies and shown to be effective
[70]. Computerized physician order entry systems and
drug interaction softwares linked to knowledge bases
could detect potential DDIs and alert prescribers to pre-
vent serious outcomes. These systems screen the drug list
before finalizing an order. In case of a potential medica-
tion error, especially a DDI, alerts are displayed and
changes in the prescription can be made. Although nu-
merous studies in different countries mentioned the po-
tential improvement of patient safety by computerized
systems, there are no studies published on the evaluation
of such systems in Iran.
It should be noted that the present review had several
limitations. First, although the comprehensive searches
were performed, we may have missed some relevant stud-
ies. It may be due to limitations of the Persian search en-
gines. To overcome this limitation, we used several search
strategies including searching bibliographies of included
studies (snowball method). In addition, we searched Goo-
gle Scholar using both Persian and English search terms.
Second, the methodologies of the included studies in our
review were heterogeneous. This made it difficult to ag-
gregate their widely varying results. Therefore, no quanti-
tative meta-analysis has been attempted. Third, we did not
include results of the unpublished studies (e.g. disserta-
tions and conference papers) in the review. This may
affect our estimations. Finally, some of the included
studies in our review had small sample sizes (Table 2)that might have led to bias. These may have limited the
generalizability of our results.
Due to the lack of studies addressing actual DDIs
among Iranian patients, the incidence of adverse events
caused by this type of medication errors remains un-
known. It is recommended that future DDIs researches
investigate the adverse events of DDIs through closely
monitoring the patients who are provided with potentially
interacting drugs. The prescribers should be aware of the
high incidence of DDIs in their prescriptions. They also
need to pay attention to patients who are frequently pre-
scribed potentially interacting drugs (e.g. digoxin, beta
blockers, NSAIDs, ACEIs, and diuretic agents). In the ab-
sence of studies assessing communication among the drug
management team (physician, nurse, and pharmacist), it is
suggested that future studies delve into aspects of this
communication. Better communication between the team
members could lead to a safe pharmacotherapy plan and
reduce the risks of adverse events caused by DDIs. In
recent years, information technology interventions have
been employed to improve medication safety and shown
to be effective in reducing the number of potential DDIs.
We suggest designing and evaluation of such information
technology interventions.
Conclusion
Although there is a large number of studies on the po-
tential DDIs in Iran, there is still no evidence of the
incidence of actual DDIs. The included studies in this
review had relatively poor quality and were heteroge-
neous in their methodologies and reporting. However,
almost all studies concluded that the incidence of DDIs
in both inpatient and outpatient settings is high. Despite
this high incidence, there is a limited number of inter-
ventional studies aimed at reducing DDIs incidence. Fi-
nally, more extensive research is needed to identify and
minimize the factors associated with the incidence of
DDIs, and to design and evaluate the effects of interven-
tions especially those that utilize information technology
to increase awareness about DDIs and decrease their in-
cidence by the drug management team.
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